.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, occupying the leading scientific research area at Sanofi.Quigley will begin Sept. 30 as the French Big Pharma's primary clinical police officer and also global head of research, Sanofi informed Fierce Biotech in an emailed claim.Quigley is switching out Frank Nestle, M.D., who left Sanofi this springtime in the middle of a global overhaul of the firm's R&D unit. Nestle, that devoted 8 years with the pharma, leapt over to Deerfield Management, where he currently works as a companion on the rehabs team and also chief executive officer of the company's therapeutic exploration and development procedures.
Quigley will definitely sign up with Sanofi coming from a San Francisco-based biotech that resides in stealth, according to his LinkedIn profile page. He's presently noted as the provider's co-founder, president and CEO.Due to the fact that August 2021, Quigley has actually worked as a project partner at SV Health and wellness Investors, a medical care fund manager with present assets in biotechs like BioAge, Cerevance, Dualitas Therapeutics and also Nimbus Therapies, to name a few. Quigley in the past held the leading place at Dualitas, a biotech that remains in secrecy, depending on to STAT.The soon-to-be Sanofi leader also recently helmed Therini Biography, an immunotherapy biotech working to create treatments for neurodegenerative ailments driven through vascular dysfunction.Prior to spending the final handful of years in biotech, Quigley possesses an even longer track record in Big Pharma, most recently working as Gilead's senior bad habit head of state of investigation the field of biology up until the summer of 2021. Just before that, he appeared greater than four years throughout a variety of management duties at Bristol Myers Squibb as well as functioned as a medical supervisor at Johnson & Johnson's Janssen upper arm before that.Sanofi claimed Quigley's objective in his brand-new function would certainly be to "optimize our likelihood of effectiveness via optimum partnerships throughout our company and also beyond, carrying best-in-class development and also developing as well as sourcing new industry-leading talent with a dedication to diversity," depending on to an internal memo acquired through STAT.